Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol VEGFC contributors: mct - updated : 22-01-2015
HGNC name vascular endothelial growth factor C
HGNC id 12682
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • five cysteine-rich motifs
  • a platelet-derived growth factor (PDGF) domain
  • mono polymer homomer , dimer
    HOMOLOGY
    interspecies homolog to rattus Vegfc (85.54 pc)
    homolog to murine Vegfc (86.27 pc)
    Homologene
    FAMILY
  • PDGF/VEGF growth factor family
  • CATEGORY signaling growth factor
    SUBCELLULAR LOCALIZATION extracellular
        plasma membrane
    basic FUNCTION
  • involved in vasculogenesis
  • active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels
  • stimulating RANKL-mediated bone resorption
  • may have a role in the progressive growth and invasion of gallbladder cancer through an autocrine mechanism (
  • regulatory role of VEGFC in initiating and potentiating neo-angiogenesis, and does promote angiogenesis via RHOA mediated pathway
  • is a neurotrophic factor that influences the dopaminergic system through multiple mechanisms
  • macrophage-derived VEGFC activates FLT4 in tip cells to reinforce NOTCH signalling, which contributes to the phenotypic conversion of endothelial cells at fusion points of vessel sprouts
  • potential role of VEGFC in the pathogenesis and development of a conjonctival pterygium through lymphangiogenesis
  • FAS and NFKB play a role in the initiation and development of breast cancer, while VEGFC appears to promote lymph node metastasis
  • important for angiogenesis in endometriosis
  • FLT4 with its cognate ligand vascular endothelial growth factor C (VEGFC), is a major mediator of lymphangiogenesis
  • acts primarily on endothelial cells, but also on non-vascular targets, for example in the CNS and immune system
  • CELLULAR PROCESS cell life, differentiation
    cell life, proliferation/growth
    PHYSIOLOGICAL PROCESS cardiovascular , angiogenesis
    PATHWAY
    metabolism
    signaling signal transduction
  • VEGFC/FLT4 signaling pathway is essential for lymphangiogenesis (the formation of lymphatic vessels from pre-existing vasculature) during embryonic development, tissue regeneration and tumor progression
  • a component
  • RSPO1-WNT-VEGFC-FLT4 signaling plays a crucial role as an endothelial-autonomous permissive cue for developmental angiogenesis
  • INTERACTION
    DNA
    RNA
    small molecule
    protein
  • high affinity for both KDR (VEGFR2) and FLTR (VEGFR3)
  • ligand of FLT4
  • NRP2 is a transmembrane receptor for the lymphangiogenic vascular endothelial growth factor C (VEGFC), plays an important role in lymphatic vessel sprouting
  • interaction between NRP2 and FLT4 mediates proper lymphatic vessel sprouting in response to VEGFC
  • CYR61 modulates the VEGFC expression of decidual natural killer cells via PI3K/AKT pathway
  • EDN1 is potent lymphangiogenic factor that relies on the interplay with hypoxic microenvironment and with VEGFA, VEGFC, and FIGF (PMID;
  • VEGFC and FIGF play a role in the induction of osteoclast differentiation through both KDR and FLT4 receptors (
  • VEGFC and its receptor FLT4 mediate lymphangiogenesis
  • in the tumor microenvironment, the reciprocal interplay between FGF2 and VEGFC collaboratively stimulated tumor growth, angiogenesis
  • PTGS2 and and VEGFC are inducers of lymphangiogenesis and their expression levels were correlated in non-Hodgkin lymphoma
  • CAPN2 may contribute to the promoter methylation of DPYSL3 to repress its transcription, leading to the metastasis of Prostate carcinoma via enhancing VEGFC expression
  • cathepsin D is a protease that can activate VEGFC as well as FIGF
  • cell & other
    REGULATION
    activated by KLK3 (KLK3 activated VEGFC specifically and efficiently through cleavage at a novel N-terminal site)
    induced by hypoxia-inducible
    TGFB1
    repressed by downregulated by VHL
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in vascular invasion, involving lymphatic vessels and lymph node, distant metastasis and poor clinical outcomes
    constitutional     --over  
    in eutopic and ectopic endometrium of endometriosis patients
    tumoral     --low  
    in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms
    tumoral     --over  
    of VEGFC and FIGF correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer (
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancer  
    high potentiality of VEGFC as a cancer drug target
    ANIMAL & CELL MODELS